You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Colorcon
Express Scripts
Moodys
Johnson and Johnson

Last Updated: April 12, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SECUKINUMAB

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for secukinumab

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00805480 Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type Psoriasis Completed Novartis Pharmaceuticals Phase 2 2008-12-01 Loading dose, four arm, double-blind, parallel group, placebo-controlled study comparing single and multiple doses of AIN457 to placebo in patients with a diagnosis of moderate to severe chronic plaque psoriasis.
NCT00928512 Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX) Completed Novartis Pharmaceuticals Phase 2 2009-07-01 This study will assess at Week 16 the efficacy and safety of AIN457 at different doses in patients with active RA despite stable MTX therapy. Treatment will continue up to Week 48 with a safety follow-up at Week 60 to assess the long term efficacy and safety of AIN457 treatment in combination with MTX in RA.
NCT00941031 AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis Completed Novartis Pharmaceuticals Phase 2 2009-07-01 The purpose of the study is to determine whether, in patients with moderate to severe plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis symptoms and the extent to which the patient's body area is affected by the disease (compared to placebo).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for secukinumab

Condition Name

Condition Name for secukinumab
Intervention Trials
Psoriasis 19
Psoriatic Arthritis 12
Plaque Psoriasis 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for secukinumab
Intervention Trials
Psoriasis 46
Arthritis 19
Arthritis, Psoriatic 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for secukinumab

Trials by Country

Trials by Country for secukinumab
Location Trials
United States 381
Japan 74
Canada 62
Italy 54
United Kingdom 53
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for secukinumab
Location Trials
California 27
Texas 25
New York 20
Arizona 18
South Carolina 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for secukinumab

Clinical Trial Phase

Clinical Trial Phase for secukinumab
Clinical Trial Phase Trials
Phase 4 18
Phase 3 52
Phase 2 23
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for secukinumab
Clinical Trial Phase Trials
Not yet recruiting 40
Recruiting 28
Completed 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for secukinumab

Sponsor Name

Sponsor Name for secukinumab
Sponsor Trials
Novartis Pharmaceuticals 68
Novartis 10
Icahn School of Medicine at Mount Sinai 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for secukinumab
Sponsor Trials
Industry 86
Other 34
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Moodys
Baxter
AstraZeneca
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.